Company / Capital Expenditures
Jade Biosciences, Inc. Capital Expenditures History
FY2021-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$142.0K
FY2023
5-year range
$142.0K / $195.0K
FY2021-FY2023
Trend
-27.2%
vs FY2022
Sector context
#168 of 195
Health Care
What the data says
Jade Biosciences, Inc.'s capital expenditures of $142,000 is lower than 86% of companies in the Health Care sector (FY2023). Declined from $181,000 to $142,000 over the past 2 years.
Based on SEC 10-K filings.
$142,000 in FY2023.
Declined from $181,000 to $142,000 over the past 2 years.
Health Care sector context is included.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 14% in Health CareTop 86% of 195This company $142.0K Sector average $117.2M
▼
-99.9% below sector average
Key checks
Key Insights
- In FY2023, capital expenditures decreased 27.2% year-over-year.
- Ranks #168 out of 195 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 6.03 (safe zone, above 2.9 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | - | - |
| FY2023 | $142.0K | -27.2% |
| FY2022 | $195.0K | +7.7% |
| FY2021 | $181.0K | - |
| FY2020 | - | - |
As of FY2023 · SEC 10-K · Updated Feb 28, 2026